Affini-T Therapeutics, a biotech with roots at Fred Hutch, raises $175M for cancer treatments
Affini-T Therapeutics, a cancer-focused biotech company with offices in Seattle, raised $175 million to pursue tech licenses to strengthen its cell therapy platform and drive programs into the clinic.
The company was co-founded by three researchers at Seattle’s Fred Hutchinson Cancer Research Center and is focused on treating patients with KRAS mutations in intractable solid tumors, which account for almost a third of all cancers.
The funding round was led by Leaps by Bayer and Vida Ventures, with additional contributions from The Parker Institute for Cancer Immunotherapy, Catalio Capital Management, Agent Capital, Alexandria Venture Investments, Erasca Ventures, Fred Hutch and others.
“With proven management, an unparalleled founding team of scientific innovators and leaders in immunology and cellular engineering, we look forward to bringing life-changing medicines to patients in need,” said Jak Knowles, CEO and co-founder of Affini-T Therapeutics.